No Photo Available

Last Update

2016-04-23T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Rhett Schiffman?

Dr. Rhett M. Schiffman MD

Chief Medical Officer and Executive Vice President Research and Development

Envisia Therapeutics Inc

Direct Phone: (919) ***-****       

Email: r***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Envisia Therapeutics Inc

4301 Emperor Blvd. Suite 200

Durham, North Carolina 27703

United States

Company Description

Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT technology platform to develop therapies for a variety of ocular con ... more

Find other employees at this company (26)

Background Information

Employment History

Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology

Allergan , Inc.

Chief Medical Officer

Neurotech S.A

Affiliations

Board Member
GRFS LLC

Board Member
Glaucoma Research Foundation

Education

B.S.

Bioengineering

Columbia University

BS

Bioengineering

Columbia University , School of Engineering and Applied Sciences

M.D.

University of Juarez , Mexico

MS

Master's degrees

Clinical Research Design and Statistical Analysis and in Health Services Administration

University of Michigan

Web References (87 Total References)


MANAGEMENT | Envisia

www.envisiatherapeutics.com [cached]

Rhett M. Schiffman, M.D.

Chief Medical Officer & Executive Vice President, Research & Development
Dr. Rhett Schiffman is Senior Vice President of Development and Chief Medical Officer at Envisia. Previously, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program through phase 1/2 clinical trials. Prior to Neurotech, he was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he played a key role in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®. Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products. Dr. Schiffman received his B.S. in Bioengineering from Columbia University and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital in Michigan and is Board Certified in both specialties and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health. He has served on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine where he sees patients and teaches residents.


Rhett Schiffman, Chief ...

ois.net [cached]

Rhett Schiffman, Chief Medical Officer and Executive Vice President, R&D - Envisia Therapeutics


ENVISIA THERAPEUTICS NAMES DR. ...

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER


ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

Envisia
...
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
Envisia Recruits Top Talent to Help Advance Promising Pipeline
RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


RESEARCH TRIANGLE PARK, NC - April ...

www.pappasventures.com [cached]

RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology.

Similar Profiles

Other People with this Name

Other people with the name Schiffman

Amy Schiffman
Knowledge Leader

Keren Schiffman
National Geographic

Seth Schiffman
KPMG LLP

Kelley Schiffman
Yale University

Robert Schiffman
Credit Suisse First Boston LLC

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory